Catalent, Inc. (NYSE:CTLT) is Westchester Capital Management LLC’s 9th Largest Position

Westchester Capital Management LLC boosted its position in Catalent, Inc. (NYSE:CTLT) by 27.9% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,445,702 shares of the company’s stock after purchasing an additional 315,525 shares during the quarter. Catalent accounts for about 3.7% of Westchester Capital Management LLC’s holdings, making the stock its 9th largest holding. Westchester Capital Management LLC’s holdings in Catalent were worth $87,566,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Brooklyn Investment Group bought a new stake in Catalent during the third quarter valued at approximately $31,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the second quarter valued at $42,000. Sentry Investment Management LLC bought a new position in Catalent in the third quarter valued at $53,000. Longfellow Investment Management Co. LLC raised its position in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter.

Catalent Price Performance

Shares of NYSE CTLT opened at $61.12 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The company has a 50 day simple moving average of $59.90 and a two-hundred day simple moving average of $58.47. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The company has a market capitalization of $11.09 billion, a price-to-earnings ratio of -27.04, a P/E/G ratio of 2.42 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period last year, the business earned ($0.10) EPS. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. Analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $63.40.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.